Ruby F. Meredith

7.6k total citations
150 papers, 5.4k citations indexed

About

Ruby F. Meredith is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Ruby F. Meredith has authored 150 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Radiology, Nuclear Medicine and Imaging, 64 papers in Pulmonary and Respiratory Medicine and 44 papers in Oncology. Recurrent topics in Ruby F. Meredith's work include Radiopharmaceutical Chemistry and Applications (52 papers), Head and Neck Cancer Studies (32 papers) and Lymphoma Diagnosis and Treatment (29 papers). Ruby F. Meredith is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (52 papers), Head and Neck Cancer Studies (32 papers) and Lymphoma Diagnosis and Treatment (29 papers). Ruby F. Meredith collaborates with scholars based in United States, Canada and United Kingdom. Ruby F. Meredith's co-authors include Sharon A. Spencer, Albert F. LoBuglio, Richard Wheeler, James A. Bonner, M.B. Khazaeli, Sui Shen, Jimmy J. Caudell, William E. Grizzle, Donald J. Buchsbaum and Susan J. Knox and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Ruby F. Meredith

150 papers receiving 5.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruby F. Meredith United States	45	2.5k	2.1k	1.7k	1.5k	1.1k	150	5.4k
Richard Fisher Australia	37	1.4k 0.6×	1.8k 0.8×	2.5k 1.5×	1.3k 0.9×	2.0k 1.9×	112	6.2k
Juliette Thariat France	36	1.0k 0.4×	2.5k 1.2×	2.0k 1.2×	1.5k 1.0×	1.7k 1.5×	489	6.2k
Leonard R. Prosnitz United States	45	1.6k 0.7×	2.2k 1.0×	1.7k 1.0×	1.1k 0.7×	1.5k 1.4×	154	7.4k
Mahmut Özsahin Switzerland	43	1.1k 0.4×	2.1k 1.0×	2.3k 1.4×	2.8k 1.8×	2.7k 2.5×	149	6.9k
Jiade J. Lu China	39	750 0.3×	2.0k 0.9×	1.5k 0.9×	1.6k 1.0×	1.6k 1.5×	186	4.5k
Christopher J. Schultz United States	37	1.3k 0.5×	3.0k 1.4×	2.0k 1.2×	3.1k 2.0×	2.4k 2.3×	138	8.7k
Luther W. Brady United States	47	2.1k 0.9×	4.4k 2.1×	2.9k 1.7×	789 0.5×	2.1k 2.0×	342	10.1k
E. Brian Butler United States	35	842 0.3×	2.1k 1.0×	1.2k 0.7×	433 0.3×	973 0.9×	227	4.7k
Joseph K. Salama United States	45	1.1k 0.4×	3.7k 1.7×	2.8k 1.7×	1.4k 0.9×	2.5k 2.4×	217	7.2k
Volker Rudat Germany	33	1.3k 0.5×	1.8k 0.9×	1.3k 0.8×	1.3k 0.9×	2.4k 2.2×	128	5.4k

Countries citing papers authored by Ruby F. Meredith

Since Specialization

Citations

This map shows the geographic impact of Ruby F. Meredith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruby F. Meredith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruby F. Meredith more than expected).

Fields of papers citing papers by Ruby F. Meredith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruby F. Meredith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruby F. Meredith. The network helps show where Ruby F. Meredith may publish in the future.

Co-authorship network of co-authors of Ruby F. Meredith

This figure shows the co-authorship network connecting the top 25 collaborators of Ruby F. Meredith. A scholar is included among the top collaborators of Ruby F. Meredith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruby F. Meredith. Ruby F. Meredith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saad, Ayman, Antonio Di Stasi, Luciano J. Costa, et al.. (2018). Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant. Bone Marrow Transplantation. 53(10). 1345–1348. 3 indexed citations

Meredith, Ruby F., Julien Torgue, Sui Shen, et al.. (2014). Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with ²¹²Pb-TCMC-Trastuzumab. Journal of Nuclear Medicine. 55(10). 1636–1642. 104 indexed citations

Meredith, Ruby F., Kevin P. Raisch, James A. Bonner, et al.. (2014). Pazopanib Combined with Radiation: In Vivo Model of Interaction. Cancer Biotherapy and Radiopharmaceuticals. 29(6). 247–250. 5 indexed citations

Vaklavas, Christos, Ruby F. Meredith, Sui Shen, et al.. (2013). Phase I Study of a Modified Regimen of ⁹⁰ Yttrium–Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma. Cancer Biotherapy and Radiopharmaceuticals. 28(5). 370–379. 3 indexed citations

Meredith, Ruby F., Zhiying You, Ronald D. Alvarez, et al.. (2012). Predictors of Long-Term Outcome from Intraperitoneal Radioimmunotherapy for Ovarian Cancer. Cancer Biotherapy and Radiopharmaceuticals. 27(1). 36–40. 11 indexed citations

Forero‐Torres, Andres, Mansoor N. Saleh, J. Galleshaw, et al.. (2010). Pilot Trial of Preoperative (Neoadjuvant) Letrozole in Combination With Bevacizumab in Postmenopausal Women With Newly Diagnosed Estrogen Receptor— or Progesterone Receptor—Positive Breast Cancer. Clinical Breast Cancer. 10(4). 275–280. 29 indexed citations

Fisher, Darrell R., Sui Shen, & Ruby F. Meredith. (2009). MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for ¹¹¹In- and ⁹⁰Y-Ibritumomab Tiuxetan. Journal of Nuclear Medicine. 50(4). 644–652. 58 indexed citations

Shen, Sui, Ruby F. Meredith, Jun Duan, et al.. (2005). Testicular Uptake and Radiation Dose in Patients Receiving Zevalin ^™ and Pretarget ^™ CC49Fusion Protein. Cancer Biotherapy and Radiopharmaceuticals. 20(1). 110–118. 3 indexed citations

Forero, Andres, Ruby F. Meredith, M.B. Khazaeli, et al.. (2005). Phase I Study of ⁹⁰ Y-CC49 Monoclonal Antibody Therapy in Patients with Advanced Non-Small Cell Lung Cancer: Effect of Chelating Agents and Paclitaxel Co-Administration. Cancer Biotherapy and Radiopharmaceuticals. 20(5). 467–478. 19 indexed citations

10.

Forero, Andres, Ruby F. Meredith, M.B. Khazaeli, et al.. (2003). A Novel Monoclonal Antibody Design for Radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals. 18(5). 751–759. 22 indexed citations

11.

Meredith, Ruby F., Sui Shen, Daniel J. Macey, et al.. (2003). Comparison of Biodistribution, Dosimetry, and Outcome from Clinical Trials of Radionuclide-CC49 Antibody Therapy. Cancer Biotherapy and Radiopharmaceuticals. 18(3). 393–404. 13 indexed citations

12.

Shen, Sui, et al.. (2003). Comparison of Methods for Predicting Myelotoxicity for Non-Marrow Targeting I-131-Antibody Therapy. Cancer Biotherapy and Radiopharmaceuticals. 18(2). 209–215. 6 indexed citations

13.

Scott, Charles, Charles W. Scarantino, Robert L. White, et al.. (2003). Phase III quality-of-life study results: impact on patients’ quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer—RTOG 97-09. International Journal of Radiation Oncology*Biology*Physics. 56(3). 832–836. 73 indexed citations

14.

Robert, Francisco, Sharon A. Spencer, Ruiwen Zhang, et al.. (2002). Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial. Lung Cancer. 37(2). 189–199. 10 indexed citations

15.

Meredith, Ruby F., Ronald D. Alvarez, Edward E. Partridge, et al.. (2001). Intraperitoneal Radioimmunochemotherapy of Ovarian Cancer: A Phase I Study. Cancer Biotherapy and Radiopharmaceuticals. 16(4). 305–315. 70 indexed citations

16.

Buck, R.H., Francisco Robert, Ruby F. Meredith, et al.. (2000). Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer. 41. 634. 2 indexed citations

17.

Tilden, Arabella B., et al.. (1998). Chimeric Antibodies with Specificity for Tumor Antigens: Demonstration of in Situ Localization to Tumors after Antibody Therapy. Biotechnic & Histochemistry. 73(4). 186–197. 2 indexed citations

18.

Alvarez, Ronald D., Edward E. Partridge, M.B. Khazaeli, et al.. (1997). Intraperitoneal Radioimmunotherapy of Ovarian Cancer with177Lu-CC49: A Phase I/II Study. Gynecologic Oncology. 65(1). 94–101. 144 indexed citations

19.

Weppelmann, B., Glenn E. Peters, Sharon A. Spencer, et al.. (1991). A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck. International Journal of Radiation Oncology*Biology*Physics. 20(2). 357–360. 7 indexed citations

20.

Okunewick, J P & Ruby F. Meredith. (1981). Graft-versus-leukemia in man and animal models. CRC Press eBooks. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact